Muplestim

Summary

Muplestim (recombinant human interleukin‑3, rhIL‑3) is an investigational cytokine that acts as a hematopoietic growth factor. Early clinical work has explored its use to stimulate blood‑cell production in conditions such as Diamond‑Blackfan anemia, chemotherapy‑induced marrow suppression, myelodysplastic syndromes, and as an adjunct in bone‑marrow transplantation. The compound is administered intravenously or subcutaneously and remains experimental, with research focused on its ability to raise neutrophil, platelet and other myeloid lineages.

Mechanism of Action

IL‑3 binds the IL‑3 receptor (CD123) expressed on multipotent hematopoietic progenitors. Receptor engagement activates JAK‑STAT, PI3K‑AKT and MAPK signaling cascades, promoting proliferation and differentiation of myeloid, erythroid and megakaryocytic precursors. In vivo the cytokine produces a multilineage boost of white cells, eosinophils and platelets and also induces modest inflammatory mediators such as IL‑6 and soluble IL‑2 receptors, reflecting its weak cytokine‑like activity.

What the Research Shows

Clinical experience with rhIL‑3 is limited to small phase I/II studies. In a series of 18 Diamond‑Blackfan anemia patients, four achieved clinically meaningful erythroid responses, with two becoming transfusion‑independent. Oncology trials in patients with advanced malignancies reported dose‑dependent rises in neutrophils, eosinophils, monocytes, lymphocytes and platelets, but no clear impact on tumor response or survival. Ex‑vivo experiments showed that combining rhIL‑3 with stem‑cell factor and G‑CSF can expand CD34+ progenitors, suggesting a role in stem‑cell mobilization for transplantation. Overall, evidence points to a robust hematopoietic stimulus but efficacy remains modest and inconsistent across indications.

Reported Benefits

Evidence from early trials indicates that rhIL‑3 can increase circulating neutrophils and platelets, improve granulopoiesis in chemotherapy‑induced marrow failure, and in a minority of Diamond‑Blackfan anemia patients achieve transfusion independence. The cytokine also enhances ex‑vivo expansion of progenitor cells, potentially shortening engraftment time after bone‑marrow transplantation. These benefits are observed at doses that produce measurable hematologic changes without major organ toxicity.

Limitations of the Evidence

Findings are derived from small, uncontrolled cohorts, limiting confidence in efficacy. Only a subset of Diamond‑Blackfan anemia patients responded, and no oncologic studies demonstrated tumor‑control benefits. Optimal dosing schedules, duration of therapy, and the best clinical contexts remain undefined. Reports of deep‑venous thrombosis and transient thrombocytopenia raise safety concerns, and the long‑term effects of repeated cytokine exposure are unknown.

Safety Considerations

The most common adverse events are mild fever, headache, flu‑like symptoms and local injection‑site reactions. rhIL‑3 induces dose‑dependent eosinophilia and can raise basophil counts. Serious events reported include deep‑venous thrombosis in two DBA responders and occasional transient thrombocytopenia in myelodysplastic syndrome patients receiving higher doses. Overall, the cytokine is regarded as generally well tolerated at studied dose ranges, but vigilance for thrombotic complications is advised.

How It Is Administered

Muplestim has been given as a single intravenous bolus followed by daily subcutaneous injections. In early studies doses ranged from 0.5 to 10 µg/kg/day (escalated every 21 days) for DBA, and 30–500 µg/m² per day for 15 consecutive days in oncology trials. The intravenous half‑life is about 20 minutes, while subcutaneous administration extends the half‑life to roughly 3‑4 hours.

Routes of Administration

Goals & Uses

• HIV-associated cytopeniaInfectious Disease / HematologyLow
• Chemotherapy-induced myelosuppression mitigationHematopoietic SupportModerate
• Stem cell mobilizationHematopoietic Stem Cell TransplantationModerate
• Aplastic anemia treatmentHematologyLow

Contraindications

• Myeloid malignancyOncologyHigh
• Hypersensitivity to muplestim or excipientsAllergyHigh

Adverse Effects

• Fever and flu-like symptomsConstitutionalCommon
• EosinophiliaHematologicUncommon
• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularUncommonLow blood pressure
• ThrombocytosisHematologyUncommon

Drug Interactions

• GM-CSF (sargramostim)Low
• G-CSF (filgrastim)Low

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with active myeloid malignancyOncologyRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization granted by EMA or predecessor bodies.
• United StatesInvestigationalInvestigated in Phase II/III trials; never received FDA approval. Development discontinued.

Muplestim was investigated in Phase II/III clinical trials primarily in the 1990s but was never approved by the FDA or other major regulatory agencies. Development was largely discontinued.

Evidence & Sources

• Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3
  Journal ArticleModerateGillio AP, et al.1993-01-01T00:00:00.000000Z
• Recombinant human interleukin 3 in clinical oncology
  Journal ArticleModeratede Vries EG, van Gameren MM, Willemse PH1993-01-01T00:00:00.000000Z
• The biology of the cytokine sequence cascade
  Journal ArticleModerateFraser JK, Lill MC, Figlin RA1996-01-01T00:00:00.000000Z
• Clinical results with recombinant human interleukin-3
  Journal ArticleModerateGanser A1993-01-01T00:00:00.000000Z
• Biologic effects of recombinant human interleukin-3 in vivo
  Journal ArticleModerateLindemann A, et al.1991-01-01T00:00:00.000000Z
• Clinical effects of recombinant human interleukin-3
  Journal ArticleModerateGanser A, et al.1991-01-01T00:00:00.000000Z

Frequently Asked Questions